A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib

INTRODUCTION: Tazemetostat is an enhancer of zeste homolog 2 (EZH2) inhibitor recommended for patients with relapsed/refractory (R/R) follicular lymphoma (FL) after demonstrating single-agent, antitumor activity in patients with wild-type or mutant EZH2. The phosphoinositide 3-kinase (PI3K) inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales: Proudman, David, Nellesen, Dave, Gupta, Deepshekhar, Adib, Deyaa, Yang, Jay, Mamlouk, Khalid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989805/
https://www.ncbi.nlm.nih.gov/pubmed/35157216
http://dx.doi.org/10.1007/s12325-022-02054-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989805/
https://www.ncbi.nlm.nih.gov/pubmed/35157216
http://dx.doi.org/10.1007/s12325-022-02054-z

Ejemplares similares